Alessandra Leone

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2898465/publications.pdf

Version: 2024-02-01

37	1,473	331670 21	414414 32
papers	citations	h-index	g-index

38	38	38	2972
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. Journal of Cellular Physiology, 2011, 226, 2378-2390.	4.1	139
2	New Perspective for an Old Antidiabetic Drug: Metformin as Anticancer Agent. Cancer Treatment and Research, 2014, 159, 355-376.	0.5	119
3	Oxidative Stress Gene Expression Profile Correlates with Cancer Patient Poor Prognosis: Identification of Crucial Pathways Might Select Novel Therapeutic Approaches. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-18.	4.0	102
4	Local and Systemic Protumorigenic Effects of Cancer-Associated Fibroblast-Derived GDF15. Cancer Research, 2014, 74, 3408-3417.	0.9	101
5	Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation. Journal of Experimental and Clinical Cancer Research, 2019, 38, 317.	8.6	82
6	Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway. Free Radical Biology and Medicine, 2015, 89, 287-299.	2.9	73
7	Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. Oncotarget, 2016, 7, 7715-7731.	1.8	67
8	Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or Raltitrexed. Cancer Biology and Therapy, 2009, 8, 782-791.	3.4	65
9	Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Cell Death and Disease, 2013, 4, e641-e641.	6.3	57
10	Targeting Autophagy in Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 7836.	4.1	54
11	Endothelial progenitor cells, defined by the simultaneous surface expression of <scp>VEGFR</scp>2 and <scp>CD</scp>133, are not detectable in healthy peripheral and cord blood. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2016, 89, 259-270.	1.5	51
12	Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Cell Death and Disease, 2013, 4, e878-e878.	6.3	50
13	Phenolic compounds and quality parameters of family farming versus protected designation of origin (PDO) extra-virgin olive oils. Journal of Food Composition and Analysis, 2015, 43, 75-81.	3.9	45
14	Enhancement of 5-FU sensitivity by the proapoptotic rpL3 gene in p53 null colon cancer cells through combined polymer nanoparticles. Oncotarget, 2016, 7, 79670-79687.	1.8	44
15	Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: results of the branch trial. Oncotarget, 2015, 6, 30394-30407.	1.8	44
16	Large extracellular vesicles: Size matters in tumor progression. Cytokine and Growth Factor Reviews, 2020, 51, 69-74.	7.2	41
17	A standardized flow cytometry network study for the assessment of circulating endothelial cell physiological ranges. Scientific Reports, 2018, 8, 5823.	3.3	38
18	Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53. Journal of Experimental and Clinical Cancer Research, 2017, 36, 177.	8.6	33

#	Article	IF	Citations
19	The Crosstalk between Cancer Stem Cells and Microenvironment Is Critical for Solid Tumor Progression: The Significant Contribution of Extracellular Vesicles. Stem Cells International, 2018, 2018, 1-11.	2.5	31
20	Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition. Journal of Experimental and Clinical Cancer Research, 2020, 39, 213.	8.6	26
21	Management of non-small cell lung cancer in the era of personalized medicine. International Journal of Biochemistry and Cell Biology, 2016, 78, 173-179.	2.8	25
22	Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models. Journal of Translational Medicine, 2022, 20, .	4.4	25
23	Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance. Frontiers in Cell and Developmental Biology, 2020, 8, 732.	3.7	22
24	Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hepâ€2 cancer cells. Proteomics, 2011, 11, 3725-3742.	2.2	21
25	Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression. Oncotarget, 2016, 7, 19559-19574.	1.8	20
26	HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation. Journal of Experimental and Clinical Cancer Research, 2022, 41, 83.	8.6	19
27	A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization) Tj ETQq1 1 0.784314 rgBT /Ov	2.7	18
28	Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake. Molecular Cancer Therapeutics, 2019, 18, 1405-1417.	4.1	18
29	Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer. JAMA Network Open, 2021, 4, e2118475.	5.9	16
30	Multidisciplinary Approach to Rectal Cancer: Are we Ready for Selective Treatment Strategies?. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 852-860.	1.7	14
31	Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients withRAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092958.	3.2	10
32	Abstract LB-219: Neoadjuvant multidisciplinary phase II study (BRANCH) of an early bevacizumab schedule plus chemo-radiation therapy in rectal cancer: efficacy, safety, and biomarkers.. , 2012, , .		1
33	Abstract 3721: Critical role of Bevacizumab schedule in combination with chemo-radiotherapy in neo-adjuvant treatment of rectal cancer: Circulating endothelial cells and FDG-PET as markers for early prediction. , 2010, , .		0
34	Abstract 4695: Predictive role of FDG PET-CT in monitoring locally advanced rectal cancer (LARC) during preoperative radiochemotherapy with an experimental bevacizumab schedule.. , 2013, , .		0
35	Abstract 5444: Modulation of ErbB receptors expression by histone deacetylase inhibitors increased the antitumor activity of an anti-ErbB3 monoclonal antibody in primary cultures from non-small cell lung cancer patients. , 2014, , .		0
36	Abstract 2569: Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer as a rationale for the innovative V-shoRT-R3 trial in locally advanced rectal cancer patients. , 2015, , .		0

#	Article	IF	Citations
37	Abstract 4745: Repurposing of valproic acid and simvastatin combination as anticancer agents in prostate cancer: synergistic interaction with docetaxel and suppression of docetaxel resistance. , 2016, , .		0